Life sciences news
-
UCB presents efficacy and safety results for zilucoplan and rozanolixizumab in generalized myasthenia gravis
Tuesday May 10th 2022
Read more
-
Oxurion announces top-line results from Part A of Phase 2 INTEGRAL trial evaluating THR-687 for treatment of diabetic macular edema (DME)
Monday May 9th 2022
Read more
-
argenx announces positive Phase 3 data from ADVANCE trial of VYVGART® (efgartigimod alfa-fcab) in adults with primary immune thrombocytopenia
Thursday May 5th 2022
Read more
-
reMYND’s novel Alzheimer program reports excellent brain exposure and safety profile in Phase 1; transitioning into Phase 2a
Tuesday May 3rd 2022
Read more
-
Mithra announces improved consolidated topline results from Donesta® Phase 3 studies and launch of recruitment for the extension of European study
Thursday April 14th 2022
Read more
-
Sequana Medical announces the completion of alfapump implantations in POSEIDON, the North American pivotal alfapump study
Tuesday April 5th 2022
Read more
-
Aligos Therapeutics selects drug candidate ALG-097558, a potent ritonavir-free oral protease inhibitor for the treatment and prevention of COVID-19
Tuesday April 5th 2022
Read more
-
Rejuvenate Biomed started a groundbreaking clinical trial and expands for future growth
Tuesday March 29th 2022
Read more
-
Become a flanders.bio member
Your news here?
-
Bone Therapeutics to strategically focus on lead cell therapy product ALLOB
Tuesday March 29th 2022
Read more
-
Jyseleca® approved in Japan for ulcerative colitis
Monday March 28th 2022
Read more
-
argenx announces positive topline Phase 3 data from ADAPT-SC study evaluating subcutaneous efgartigimod for generalized myasthenia gravis
Tuesday March 22nd 2022
Read more
More info?
Contact us
Ellen Telleir
Communication Coordinator
